Date: 2017-09-06
Type of information: Research agreement
Compound: Bicycles
Company: Bioverativ (USA - MA) Bicycle Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases - Hematological diseases
Type agreement: research - development - R&D
Action mechanism:
- peptide. Bicyclic peptides (Bicycle®) are a novel class of small molecule medicines designed to overcome many of the limitations of existing drug modalities. They can be used as standalone therapeutic entities or coupled to deliver a variety of therapeutic payloads.
- Bicycles combine attributes of antibodies, small molecules and peptides within one molecule, enabling high selectivity and affinity while simultaneously being able to penetrate and bind to the target(s) of interest within the body.
Disease: hemophilia, sickle cell disease
Details:
- • On September 6, 2017, Bioverativ and Bicycle Therapeutics announced a research collaboration focused on the discovery, development and commercialization of innovative therapies for hemophilia and sickle cell disease. The collaboration will seek to identify and develop Bicycles to treat rare blood disorders.
- Bicycle Therapeutics will be responsible for leading initial discovery activities through lead optimization to candidate selection for two programs. Bioverativ will lead preclinical and clinical development, as well as subsequent marketing and commercialization. Bioverativ will reimburse Bicycle for internal and external program-related costs.
Financial terms:
- Upon execution of the agreement, Bicycle will receive a $10 million upfront payment and near-term research and development funding of $4.2 million. Bicycle is eligible to receive up to $410 million related to development, regulatory and commercialization milestones for products planned under the two programs, as well as tiered single to low double-digit royalties related to product sales. Additional terms of the transaction are not being disclosed.
Latest news:
Is general: Yes
